Janux Therapeutics, Inc.
Develops tumor-activated T cell engager immunotherapies for cancer treatment.
JANX | US
Overview
Corporate Details
- ISIN(s):
- US47103J1051
- LEI:
- Country:
- United States of America
- Address:
- 10955 VISTA SORRENTO PARKWAY, 92130 SAN DIEGO
- Website:
- https://www.januxrx.com/
- Sector:
- Manufacturing
Description
Janux Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies for cancer. The company utilizes its proprietary Tumor Activated T Cell Engager (TRACTr) platform to engineer therapeutics designed for conditional activation within the tumor microenvironment. This technology aims to create highly specific treatments that direct the immune system to attack cancer cells while minimizing systemic toxicity associated with conventional T cell engagers. Janux is advancing a pipeline of these precision-engineered therapies to address solid tumors.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Janux Therapeutics, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Janux Therapeutics, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Janux Therapeutics, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
